Nuvectis Pharma
NVCT
36 hedge funds and large institutions have $12.6M invested in Nuvectis Pharma in 2023 Q4 according to their latest regulatory filings, with 5 funds opening new positions, 16 increasing their positions, 6 reducing their positions, and 2 closing their positions.
167% more repeat investments, than reductions
Existing positions increased: 16 | Existing positions reduced: 6
150% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 2
9% more funds holding
Funds holding: 33 → 36 (+3)
1.32% more ownership
Funds ownership: 7.41% → 8.73% (+1.3%)
23% less capital invested
Capital invested by funds: $16.5M → $12.6M (-$3.84M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$303K |
| 2 |
BlackRock
New York
|
+$254K |
| 3 |
GCP
GSA Capital Partners
London,
United Kingdom
|
+$244K |
| 4 |
Renaissance Technologies
New York
|
+$235K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$229K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MWM
Moran Wealth Management
Naples,
Florida
|
-$215K |
| 2 |
Marshall Wace
London,
United Kingdom
|
-$101K |
| 3 |
TRCT
Tower Research Capital (TRC)
New York
|
-$53.5K |
| 4 |
DWA
Dorsey Wright & Associates
Pasadena,
California
|
-$18K |
| 5 |
California State Teachers Retirement System (CalSTRS)
West Sacramento,
California
|
-$3.72K |
NVCT Hedge Fund Activity: Q4 2023 in Review
36 of the 6,869 institutional investors tracked by Wall St. Rank reported a position in Nuvectis Pharma (NVCT) for Q4 2023, worth a combined $12.6M — down 23% from $16.5M a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new NVCT positions and 2 closed out — a net gain of 3 holders — while 16 added to existing stakes and 6 trimmed.
The largest buyer was Millennium Management, opening a new position worth an estimated $303K. The largest seller was Moran Wealth Management, exiting entirely with an estimated $215K sold.
- 36 institutional investors held Nuvectis Pharma (NVCT) as of Q4 2023, up from 33 in Q3 2023.
- Funds reported $12.6M of Nuvectis Pharma stock for Q4 2023, down 23% quarter-over-quarter.
- 5 funds opened new Nuvectis Pharma positions in Q4 2023 and 2 closed out, a net change of +3 holders.
- The largest Nuvectis Pharma buyer in Q4 2023 was Millennium Management, an estimated $303K added.
- The largest Nuvectis Pharma seller in Q4 2023 was Moran Wealth Management, an estimated $215K sold.
Based on aggregated 13F filings for Q4 2023.